Braidwell LP Acquires 250,800 Shares of Globus Medical, Inc. $GMED

Key Points

• Braidwell LP more than doubled its stake in the quarter, buying an additional 250,800 shares to hold 498,000 shares (about 0.37% of Globus) valued at $28.52 million.
• Globus reported a beat with EPS $1.28 vs. $1.06 and revenue $826.4M (up 25.7% YoY), and analysts have raised targets and ratings toward a consensus "Moderate Buy" with an average target of about $104.36.
• At the same time, insiders sold 35,594 shares in the last 90 days (including the CFO and an EVP), with insiders owning 18.51% of the stock, a notable counterpoint to the heavy institutional buying.

Braidwell LP grew its holdings in Globus Medical, Inc. (NYSE:GMED - Free Report) by 101.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 498,000 shares of the medical device company's stock after buying an additional 250,800 shares during the quarter. Braidwell LP owned 0.37% of Globus Medical worth $28,520,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC raised its position in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock worth $27,000 after purchasing an additional 197 shares in the last quarter. Advisors Asset Management Inc. bought a new position in Globus Medical during the second quarter worth about $28,000. First Horizon Corp acquired a new stake in Globus Medical during the third quarter valued at approximately $31,000. Parallel Advisors LLC grew its stake in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock valued at $32,000 after purchasing an additional 173 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Globus Medical in the 3rd quarter valued at approximately $36,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Globus Medical news, CFO Kyle Kline sold 3,594 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $363,353.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Kelly Huller sold 20,000 shares of the firm's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 35,594 shares of company stock worth $3,332,253. 18.51% of the stock is owned by corporate insiders.

Globus Medical Price Performance

NYSE GMED opened at $84.81 on Friday. The stock's 50 day simple moving average is $90.71 and its 200 day simple moving average is $78.37. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The firm has a market cap of $11.47 billion, a PE ratio of 21.52, a price-to-earnings-growth ratio of 1.99 and a beta of 1.05.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.22. The firm had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The business's revenue for the quarter was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.84 EPS. As a group, equities analysts expect that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a "Strong‑Buy" rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average "Moderate Buy" rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of "Moderate Buy" by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

Analysts Set New Price Targets

Several research firms recently commented on GMED. Wells Fargo & Company raised their target price on Globus Medical from $98.00 to $104.00 and gave the stock an "overweight" rating in a research report on Thursday, February 26th. BTIG Research reiterated a "neutral" rating on shares of Globus Medical in a research note on Tuesday, December 30th. Citigroup reissued a "market perform" rating on shares of Globus Medical in a report on Thursday, January 8th. Zacks Research upgraded shares of Globus Medical from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 3rd. Finally, Barclays upped their target price on shares of Globus Medical from $118.00 to $123.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $104.36.

Globus Medical Company Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.